GlassScriptPhysician profile
Mary K Arnold
NPI 1952899593
$1,799.14
in general payments reported to CMS, 2019-2025
29 companies · $27.22 in 2025
The $27.22 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $899 · 2022: $330 · 2023: $455 · 2024: $88.09 · 2025: $27.22.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $571.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $570.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $254.63 | 2021-2023 | Afrezza |
| Abbvie INC. | $240.34 | 2021-2023 | |
| Novo Nordisk INC | $197.09 | 2021 | |
| Exact Sciences Corporation | $167.61 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $111.15 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $80.01 | 2021-2022 | |
| Corcept Therapeutics | $74.12 | 2021-2023 | Korlym |
| Astrazeneca Pharmaceuticals LP | $66.42 | 2021 | |
| Esperion Therapeutics, INC. | $60.11 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $57.72 | 2021 | |
| Glaxosmithkline, LLC. | $51.72 | 2022-2023 | Shingrix |
| Biohaven Pharmaceuticals, INC. | $46.66 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $41.13 | 2021 | |
| Sanofi-Aventis U.S. LLC | $41.06 | 2021 | |
| Cardiovascular Systems INC. | $36.97 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $36.50 | 2022 | |
| Pfizer INC. | $29.13 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $24.34 | 2021-2022 | |
| Dexcom, INC. | $22.67 | 2022 | |
| Insulet Corporation | $22.47 | 2023 | Omnipod |
| Sunovion Pharmaceuticals INC. | $22.13 | 2021 | |
| Alkermes, INC. | $19.29 | 2023 | Lybalvi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.70 | 2022 | |
| Amarin Pharma, INC. | $14.76 | 2021 | |
| Lupin INC. | $13.92 | 2021 | |
| Medtronic, INC. | $13.44 | 2021 | |
| Merck Sharp & Dohme LLC | $12.92 | 2022 | |
| Nestle Healthcare Nutrition INC. | $11.98 | 2021 | |
| Ibsa Pharma INC. | $11.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Arnold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.